In addition, CXCL5‐neutralizing antibodies effectively attenuated the inflammatory response, diffused alveolar injury and pulmonary edema, and reduced the expression levels of MMP‐2 and MMP‐9 in ARDS mouse models.292. This evidence concerns the gene MMP9 and acute respiratory distress syndrome.